< Back to the list of products
Fevaxyn FeLV, suspension for injection for cats
- Inactivated vaccine presented in glass vials, for the active immunization of healthy cats 9 weeks and older against Feline Leukaemia Virus (FeLV).
- OIncludes whole cell FeLV technology produced using bioreactor technology that confers the most consistent degree of protection against persistent viraemia.
Description
Fevaxyn FeLV is a milky white suspension for injection containing inactivated, adjuvanted
Feline Leukaemia Virus, subgroups A and B, 1.0 RP* per 1 ml dose.
*RP = relative protection
| Adjuvants: | |
|---|---|
| Carbopol | 1 mg |
| Excipients | |
| Formaldehyde | |
INDICATIONS
The vaccine is used for the prevention of persistent viraemia associated with feline leukaemia
virus infection.
Onset of immunity is 2 weeks after primary vaccination and the duration of immunity is one
year.
CONTRAINDICATIONS
Do not vaccinate sick cats.
ADVERSE REACTIONS
Local injection site reactions such as swelling, pain, pruritis or hair loss may occur post
vaccination. A small percentage of vaccinated cats may also develop post vaccination
reactions such as fever, vomiting, anorexia and lethargy.
Hypersensitivity reactions such as urticaria or facial oedema, sometimes accompanied by
respiratory signs have been reported.
TARGET SPECIES
Cats
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
The vaccination of female cats prior to mating is recommended to provide maternally derived
antibody for the kittens.
One full dose of 1 ml of the vaccine is to be administered subcutaneously to cats of 9 weeks
of age or older.
Vaccination Schedule
Primary vaccination:
A single dose of Fevaxyn FeLV should be administered from 9 weeks of age followed by a
second injection after an interval of 3 weeks.
Booster vaccination:
Booster vaccinations are recommended every 12 months.
Overdose
Administration of an overdose does not result in significantly worse adverse reactions to those
seen after administration of a single dose.
WITHDRAWAL PERIOD
Not applicable.
SHELF LIFE
Shelf-life of the veterinary medicinal product as packaged for sale: 12 months
SPECIAL STORAGE PRECAUTIONS
Store and transport refrigerated (2°C - 8°C).
Protect from light.
Do not freeze.
SPECIAL WARNINGS
Do not vaccinate cats during pregnancy.
Vaccination has no known beneficial effect in cats already infected with FeLV. Therefore,
diagnostic testing of cats for the presence of feline leukaemia (FeLV) core protein p27 in
serum prior to vaccination may be advisable.
Special precautions for use in animals
In the event of allergic reaction, immediate treatment should be given using epinephrine
(adrenaline) intramuscularly and/or a short acting glucocorticoid (e.g. dexamethasone sodium
phosphate) intravenously.
Animals that have received immunosuppressive drugs should not be vaccinated until an
interval of at least four weeks has elapsed.
No information is available on the safety and efficacy from the concurrent use of this vaccine
with any other product except Katavac CHP or Eclipse IV provided that these two vaccines
are authorised. It is therefore recommended that no other vaccines than these should be
administered within 14 days before or after vaccination with the product.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection/ingestion/spillage onto skin, seek medical advice
immediately and show the package insert or label to the physician.
OTHER INFORMATION
ATC Vet Code: QI06AA01
Nature and composition of immediate packaging
Vial: Type I (Ph.Eur.) borosilicate glass. 2 ml capacity
Closure: Type I (Ph.Eur.) bromobutyl rubber stoppers sealed with aluminium crimp caps
Pack Sizes
Packs with 10 x 1 ml doses.
Any unused vaccine or waste material should be disposed of in accordance with local
requirements.
FURTHER INFORMATION
The antigen was selected on its immunogenic property. The FeLV subgroup-A Rickard strain
is known to cause the typical symptoms of Feline Leukaemia. Subgroup-B and subgroup-C
are recombinations of subgroup-A with cat genome sequences. Subgroup-A and B are part of
Fevaxyn FeLV vaccine antigen and should also immunise against subgroup-C.
After infection with FeLV, cats develop either a transient or persistent viraemia. Persistent
viraemia is strongly correlated with degenerative, proliferative or neoplastic changes of cells
of the haemopoietic system resulting in immunosuppression, leukaemia or tumours. On the
other hand, transiently viraemic cats may develop a protective immunity resulting in either the
elimination of cells with integrated FeLV genome or a persistent, non-productive latent
infection.
